<DOC>
	<DOCNO>NCT02176499</DOCNO>
	<brief_summary>Study compare natriuretic effect telmisartan placebo mild-to-moderate hypertensive patient control sodium diet well explore effect telmisartan norepinephrine , plasma renin activity ( PRA ) , plasma aldosterone , urine potassium , creatinin , chloride , bicarbonate uric acid excretion . Additionally assess whether natriuretic effect disappear treatment telmisartan stop . The effect telmisartan seat clinic blood pressure relationship urine sodium loss decrease ambulatory blood pressure first dose assess descriptively . Assessment safety also consider .</brief_summary>
	<brief_title>Natriuretic Effect Telmisartan Versus Placebo Patients With Mild-to-Moderate Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Natriuretic Agents</mesh_term>
	<criteria>Mildtomoderate hypertension define morning mean diastolic blood pressure ≥ 90 ≤ 115 mmHg mean systolic blood pressure ≤ 200 mmHg five minute seat position end three week placebo runin treatment Male female patient 18 65 year age , inclusive . Patients 60 65 year age must screen 24hour urine creatinine clearance rate ≥ 1 mL/sec Ability provide write informed consent Premenopausal woman ( last menstruation ≤ one year start screen ) Postmenopausal woman ( last menstruation &gt; one year start screen hysterectomy oophorectomy ) Who &lt; three month stable estrogen replacement therapy screening Who progesterone therapy time trial Known suspect secondary hypertension Hepatic and/or renal dysfunction define follow laboratory parameter : ALT ( alanine aminotransferase ) AST ( aspartate aminotransferase ) great two time upper limit reference range Serum creatinine great 2.3 mg/dL Bilateral renal artery stenosis ; renal artery stenosis solitary kidney ; postrenal transplant NYHA ( New York Heart Association ) functional class CHF ( chronic heart failure ) IIIIV Unstable angina , myocardial infarction cardiac surgery within precede three month Stroke within precede six month PTCA ( percutaneous transluminal coronary angioplasty ) within precede three month History angioedema Sustained ventricular tachycardia , atrial fibrillation , clinically relevant cardiac arrhythmia determine clinical Investigator Hypertrophic obstructive cardiomyopathy , aortic stenosis , hemodynamically relevant stenosis aortic mitral valve Administration digoxin digitalistype drug Patients insulindependent noninsulindependent diabetes mellitus History drug alcohol dependency Use antihypertensive agent diuretic , ACE inhibitor , angiotensin II antagonist , αblockers , βblockers , calcium channel antagonist , direct vasodilator time trial Administration nonantihypertensive medication know affect blood pressure ( e.g. , oral corticosteroid , MAO ( monoamine oxidase ) inhibitor , nitrate ) time trial Chronic administration high dos NSAIDS aspirin ( e.g. , ibuprofen rheumatoid arthritis osteoarthritis total daily dose excess 1600 mg , aspirin excess 2 Gm per day ) Chronic use salt substitute contain potassium chloride ; potassium supplement ; extreme dietary restriction Clinically significant sodium depletion define serum sodium level le 130 mEq/L Clinically significant hyperkalemia define serum potassium level great 6.0 mEq/L . Clinically significant hypokalemia define serum potassium level le 3.0 mEq/L Patients receive investigational therapy within one month signing informed consent form . Note patient participate previous telmisartan study may participate study provide least one month discontinue previous study sign consent present study Known hypersensitivity component telmisartan Any clinical condition , opinion principal Investigator , would allow safe completion protocol safe administration trial medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>